Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble's license to market the insomnia drug Silenor lets the firm re-enter the Rx drug market without development costs and opens the door to a potential OTC switch
You may also be interested in...
Somaxon Sees “Clear Path” For Silenor Sleep Aid Switch
Somaxon Pharmaceuticals expects to make Silenor sleep aid available OTC in five to seven years.
Somaxon Sees “Clear Path” For Silenor Sleep Aid Switch
Somaxon Pharmaceuticals expects to make Silenor sleep aid available OTC in five to seven years.
Somaxon Sees “Clear Path” For Silenor Sleep Aid Switch
Somaxon Pharmaceuticals expects to make Silenor sleep aid available OTC in five to seven years.